Form 4: Immix Biopharma Director Yekaterina Chudnovsky Reports Significant Indirect Ownership and New Stock Option Grant

Immix Biopharma, Inc. Director and 10% Owner Yekaterina Chudnovsky has reported an indirect beneficial ownership of over 3.2 million common shares and the grant of 33,000 stock options.

Summary

• Yekaterina Chudnovsky, a Director and 10% Owner of Immix Biopharma, Inc. (IMMX), filed a Form 4 statement regarding her beneficial ownership.
• The filing indicates an indirect beneficial ownership of 3,241,076 shares of Common Stock held by GKCC, LLC, where Ms. Chudnovsky is the sole member and manager.
• Ms. Chudnovsky was granted 33,000 stock options on June 20, 2025, with an exercise price of $2.24 per share.
• These stock options will vest in twelve equal monthly installments following the grant date, contingent upon her continued service on the Board of Directors.
• The options have an expiration date of June 20, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of stock options to a director and 10% owner, coupled with significant existing indirect ownership, indicates strong insider alignment and confidence in the company's future performance. While a routine compensation event, it signals a vested interest from a key stakeholder.

Positives

• The grant of stock options to a director and 10% owner aligns management's interests with shareholder value, as the options' value increases with the company's stock price.
• Continued significant indirect ownership by a director and 10% owner (3,241,076 shares) demonstrates a strong vested interest in the company's long-term success.

Risks

• The vesting of the granted stock options is subject to the reporting person's continued service on the Board of Directors, meaning the options could be forfeited if service ceases prematurely.

Future Outlook

The granted stock options are subject to a vesting schedule over twelve equal monthly installments, contingent on the director's continued service, indicating future equity accumulation tied to ongoing board participation.

Industry Context

This filing is a standard disclosure of insider trading activity, common in the biopharma industry and all publicly traded sectors, reflecting a director's compensation and ownership stake. It indicates ongoing alignment between the company's leadership and its equity performance.

Comparison to Industry Standards

• A Form 4 filing primarily reports individual insider transactions and does not provide sufficient data for a comprehensive comparison of financial results or operational performance against industry benchmarks or specific comparable companies/projects. The reported stock option grant and beneficial ownership are typical forms of director compensation and equity alignment within the biopharma industry, but specific comparisons would require detailed compensation reports from peer companies.

Related Party Transactions

• Yekaterina Chudnovsky is the sole member and manager of GKCC, LLC, which indirectly holds 3,241,076 shares of Immix Biopharma Common Stock. This constitutes a related party transaction as the beneficial ownership is through an entity controlled by the reporting person.

Stakeholder Impact

• Shareholders: The grant of stock options to a director and 10% owner can be viewed positively as it aligns management's incentives with shareholder returns. The significant indirect ownership also indicates a strong commitment from a key insider.
• Employees: No direct impact mentioned, but strong insider alignment can indirectly foster a more stable and growth-oriented environment.

Next Steps

• The granted stock options will vest in twelve equal monthly installments following the grant date of June 20, 2025, subject to Yekaterina Chudnovsky's continued service on the Board of Directors.

Key Dates

Keywords

Immix Biopharma, IMMX, SEC Form 4, Beneficial Ownership, Stock Option Grant, Insider Ownership, Director Compensation, Biopharma, Equity Compensation